FDA Eyes Flolipid Approval After Company Misses Annual Reports
Published Date: 11/18/2026
Notice
Summary
The FDA plans to pull the approval for Salerno Pharmaceuticals' Flolipid Suspension because the company hasn’t submitted required yearly reports. Salerno has until December 18, 2026, to ask for a hearing to explain themselves. This affects anyone using or selling Flolipid and could change its availability soon.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
FDA proposes to withdraw Flolipid approval
The FDA is proposing to withdraw approval of NDA 206679 for Flolipid suspension (20 mg/5 mL and 40 mg/5 mL) because Salerno Pharmaceuticals repeatedly failed to file required annual reports under 21 CFR 314.81. If approval is withdrawn, the Flolipid products covered by this NDA may not be lawfully introduced into interstate commerce.
Opportunity to seek hearing and submit evidence
Salerno Pharmaceuticals may request a hearing on the proposed withdrawal by December 18, 2026, and must submit all supporting data and analyses by January 19, 2027. Other interested persons may submit electronic or written comments by January 19, 2027; confidential submissions have special paper-submission procedures.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-23351, Rulemaking To Provide That N-acetyl-L-cysteine Is Not Excluded From the Dietary Supplement Definition
The FDA wants to officially say that N-acetyl-L-cysteine (NAC) can be sold as a dietary supplement. This means companies can legally put NAC in their products without breaking the rules, as long as they follow other laws. People and businesses making or selling supplements with NAC should share their thoughts by January 19, 2027.
2026-20848, Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods
The FDA is changing food rules to allow salt substitutes in many standardized foods, helping companies make lower-sodium options. This move aims to cut heart disease risks by reducing sodium without changing how foods basically taste or look. The new rule kicks in December 14, 2026, and food makers have until November 12, 2026, to raise any concerns, with no big costs expected.
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
Previous / Next Documents
Previous: 2026-23412, Applications for Inclusion on the Binational Panels Roster Under the United States-Mexico-Canada Agreement
The U.S. Trade Representative is looking for qualified people to join the binational panels roster under the USMCA for April 2027 to March 2028. These panels review trade disputes about unfair duties between the U.S., Mexico, and Canada. If you want to apply, make sure to submit your application by December 4, 2026—this is your chance to help keep trade fair and square!
Next: 2026-23414, Determination That BROMFED-DM (Brompheniramine Maleate; Dextromethorphan Hydrobromide; Pseudoephedrine Hydrochloride) Syrup, 2 Milligrams/5 Milliliters; 10 Milligrams/5 Milliliters; 30 Milligrams/5 Milliliters, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The FDA has confirmed that BROMFED-DM syrup, in all its strengths, wasn’t pulled from the market because of safety or effectiveness problems. This means generic drug makers can keep getting approval to sell their versions, as long as they follow the rules. If you rely on this cough and cold syrup, no worries—it’s staying available and safe for now!